Search
Flecainide
go.drugbank.com/drugs/DB01195ApprovedInvestigationalWithdrawn[A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. … [L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.[L8875]
Synonyms: N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamideProducts: FLECAINIDE EGMometasone
go.drugbank.com/drugs/DB00764ApprovedInvestigationalMometasone is a corticosteroid not currently used in medical products. [Mometasone furoate] however, is still in use.
Products: MOMETASONE EGIcatibant
go.drugbank.com/drugs/DB06196ApprovedInvestigational[A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema. … swelling, thus demonstrating bradykinin involvement in the disease pathophysiology.
Categories: Drugs Used in Hereditary AngioedemaProducts: ICATIBANT EG, Icatibant STADA 30 mg Injektionslösung in einer FertigspritzeLevetiracetam
go.drugbank.com/drugs/DB01202ApprovedInvestigationalIt was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs). … interactions[L8606,L8600,L8615] - these characteristics make it a desirable choice over other AEDs, a class of drugs notorious for having generally narrow therapeutic indexes and a propensity for involvement in
Products: Levetiracetam ER, LEVETIRACETAM EGDarifenacin
go.drugbank.com/drugs/DB00496ApprovedInvestigationalThis block reduces the urgency to urinate and so it should not be used in people with urinary retention. … It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments.
Products: DARUCIL® ER 15 MGIopamidol
go.drugbank.com/drugs/DB08947ApprovedInvestigationalIopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.
Categories: Compounds used in a research, industrial, or household settingProducts: PAMIRAY 370 ENJ. 50 ML 0,755 MG FLAKON, 1 ADET, PAMIRAY 370 ENJ. 100 ML 0,755 MG FLAKON, 1 ADETTrospium
go.drugbank.com/drugs/DB00209ApprovedInvestigational[L6208] An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. … [L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.[L6211]
Products: Trospium Chloride ERPropranolol
go.drugbank.com/drugs/DB00571ApprovedInvestigational[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.[L6904]
Products: Propranolol HCL ER, Propranolol hcl ERSilodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigational[A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada. … It is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults.
Categories: Drugs Used in Benign Prostatic HypertrophyProducts: SILODOSINA EGGefitinib
go.drugbank.com/drugs/DB00317ApprovedInvestigationalActing in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. … Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer.
Synonyms: N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamineProducts: GEFITINIB EG